Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2014 Sep 13

PMID 25212275

Citations 47

Authors

X Cabagnols

J P Defour

V Ugo

J C Ianotto

P Mossuz

J Mondet

F Girodon

J H Alexandre

O Mansier

J F Viallard

E Lippert

A Murati

M J Mozziconacci

P Saussoy

M C Vekemans

L Knoops

F Pasquier

V Ribrag

E Solary

I Plo

S N Constantinescu

N Casadevall

W Vainchenker

C Marzac

O Bluteau

Affiliations

Soon will be listed here.

Citing Articles

-negative myeloproliferative neoplasms in the era of next-generation sequencing.

Mroczkowska-Bekarciak A, Wrobel T Front Genet. 2023; 14:1241912.

PMID: 37745842 PMC: 10514516. DOI: 10.3389/fgene.2023.1241912.

Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China.

Fu R, Dong H, Zhang D, Zhou H, Zhang X, Huang Y Ann Hematol. 2023; 102(8):2097-2107.

PMID: 37354213 DOI: 10.1007/s00277-023-05317-z.

Mutation-Driven S100A8 Overexpression Confers Aberrant Phenotypes in Type 1 -Mutated MPN.

Wang Y, Chen Y, Lai Y, Wang M, Chen Y, Wu Y Int J Mol Sci. 2023; 24(10).

PMID: 37240094 PMC: 10217897. DOI: 10.3390/ijms24108747.

Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology.

Combaluzier S, Quessada J, Abbou N, Arcani R, Tichadou A, Gabert J Cells. 2023; 12(6).

PMID: 36980287 PMC: 10047531. DOI: 10.3390/cells12060946.

Structural and Dynamic Differences between Calreticulin Mutants Associated with Essential Thrombocythemia.

Radjasandirane R, de Brevern A Biomolecules. 2023; 13(3).

PMID: 36979444 PMC: 10046389. DOI: 10.3390/biom13030509.

References

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

Levine R, Gilliland D . Myeloproliferative disorders. Blood. 2008; 112(6):2190-8. PMC: 2962533. DOI: 10.1182/blood-2008-03-077966. View

Campbell P, Scott L, Buck G, Wheatley K, East C, Marsden J . Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005; 366(9501):1945-53. DOI: 10.1016/S0140-6736(05)67785-9. View

Chi J, Nicolaou K, Nicolaidou V, Koumas L, Mitsidou A, Pierides C . Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis. Leukemia. 2013; 28(5):1152-4. PMC: 4017256. DOI: 10.1038/leu.2013.382. View

Maffioli M, Genoni A, Caramazza D, Mora B, Bussini A, Merli M . Looking for CALR mutations in familial myeloproliferative neoplasms. Leukemia. 2014; 28(6):1357-60. DOI: 10.1038/leu.2014.33. View

Nangalia J, Massie C, Baxter E, Nice F, Gundem G, Wedge D . Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405. PMC: 3966280. DOI: 10.1056/NEJMoa1312542. View

Klampfl T, Gisslinger H, Harutyunyan A, Nivarthi H, Rumi E, Milosevic J . Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25):2379-90. DOI: 10.1056/NEJMoa1311347. View

Rumi E, Harutyunyan A, Pietra D, Milosevic J, Casetti I, Bellini M . CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood. 2014; 123(15):2416-9. DOI: 10.1182/blood-2014-01-550434. View

10.

Tefferi A, Lasho T, Finke C, Knudson R, Ketterling R, Hanson C . CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014; 28(7):1472-7. DOI: 10.1038/leu.2014.3. View

11.

Tefferi A, Wassie E, Guglielmelli P, Gangat N, Belachew A, Lasho T . Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014; 89(8):E121-4. DOI: 10.1002/ajh.23743. View

12.

Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel J, Brunel J, Mermel C . Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014; 123(22):e123-33. PMC: 4041169. DOI: 10.1182/blood-2014-02-554634. View

13.

Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I . Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014; 123(14):2220-8. DOI: 10.1182/blood-2013-11-537167. View

14.

Beer P, Campbell P, Scott L, Bench A, Erber W, Bareford D . MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008; 112(1):141-9. DOI: 10.1182/blood-2008-01-131664. View